A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7

Basit Öğe Kaydı
dc.contributor.authorPassaro, A.
dc.contributor.authorGirard, N.
dc.contributor.authorAbreu, D. Rodriguez
dc.contributor.authorGumus, M.
dc.contributor.authorWu, Y-l.
dc.contributor.authorSyrigos, K.
dc.contributor.authorRamlau, R.
dc.date.accessioned2025-11-16T19:35:06Z
dc.date.issued2025
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipSummit Therapeutics, Inc.
dc.description.sponsorshipSummit Therapeutics, Inc.
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15550
dc.identifier.volume20
dc.identifier.wosWOS:001469772400045
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleA randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu